Voyager Takes a Hit After FDA Places Hold on Gene Therapy for Huntington's Disease

Shares of Voyager Therapeutics were down more than 11% in premarket trading after the company announced a clinical hold was placed on its experimental gene therapy treatment for Huntington’s disease before it heads into the clinic.